SRD5A2 and emerging therapies in androgen-driven disorders.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and therapeutic targets with no new empirical human data or systematic methodology.
PubMed 41501168 · doi:10.1038/s41585-025-01112-9
What was done
This narrative review synthesized current literature on the biological role of steroid 5α-reductase type 2 (SRD5A2) and the use of 5α-reductase inhibitors (5ARIs) in benign prostatic hyperplasia (BPH), prostate cancer, and androgenic alopecia. It examined the impact of genetic polymorphisms, epigenetic silencing, and inflammation on SRD5A2 regulation and treatment response.
What was found
The abstract reports no numerical data or statistical findings. It notes that SRD5A2 is the dominant isoform in the prostate mediating testosterone conversion to dihydrotestosterone, and identifies regulatory alterations in SRD5A2 as candidates for personalized 5ARI treatment strategies.
Why it matters
The paper highlights how understanding SRD5A2 regulatory variations could inform targeted 5ARI therapies to improve long-term outcomes in BPH and other androgen-dependent diseases.
Limits
As a narrative review, it presents no original clinical data, sample size, or systematic search methodology. Quantitative effectiveness and clinical validity of proposed biomarkers are not detailed in the abstract.
Cited by
- supports 5-alpha reductase inhibitor drugs block the enzymatic conversion of testosterone to dihydrotestosterone (DHT).